INS and benign prostatic hyperplasia: Given our underlying hypothesis that insulin drives BPH pathophysiology, we completed a post hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial to assess the association between insulin resistance and both prostate size at baseline and PV growth over time.